Allied Biotech (ROCO:1780) Shares Outstanding (EOP): 96.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1780 Allied Biotech Corp ROCO:1780
77 GF Score
Price NT$22.30
GF Value NT$20.77
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Allied Biotech Shares Outstanding (EOP)?

Allied Biotech ROCO:1780 -1.76% 77 Shares Outstanding (EOP) is 96.2 Mil as of Dec. 2025. GuruFocus rates ROCO:1780 with a GF Score™ of 77/100 and a GF Value™ of NT$20.77 (Fairly Valued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Allied Biotech's shares outstanding for the quarter that ended in Dec. 2025 was 96.2 Mil.

Allied Biotech's quarterly shares outstanding stayed the same from Sep. 2025 (96.2 Mil) to Dec. 2025 (96.2 Mil).

Allied Biotech's annual shares outstanding increased from Dec. 2024 (96.0 Mil) to Dec. 2025 (96.2 Mil). It means Allied Biotech issued new shares from Dec. 2024 to Dec. 2025 .


Allied Biotech  (ROCO:1780) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Allied Biotech Shares Outstanding (EOP) Related Terms


Allied Biotech Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Allied Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied Biotech Shares Outstanding (EOP) Chart

Allied Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.35 95.39 95.97 96.02 96.24

Allied Biotech Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.02 96.02 96.02 96.24 96.24

ROCO:1780 vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allied Biotech Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Allied Biotech's Shares Outstanding (EOP) falls into.


ROCO:1780
77GF Score
Allied Biotech Corp ROCO:1780
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allied Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 96.2 Mil mean?
Allied Biotech (ROCO:1780) has a Shares Outstanding (EOP) of 96.2 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Allied Biotech and its competitors.
Is Allied Biotech's Shares Outstanding (EOP) too high?
Allied Biotech's current Shares Outstanding (EOP) is 96.2 Mil. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's Shares Outstanding (EOP) compare to ZTS and UTHR?
Allied Biotech's Shares Outstanding (EOP) of 96.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Allied Biotech and its competitors. Allied Biotech's current Shares Outstanding (EOP) is 96.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.77, compared to a current price of NT$22.30 — trading 7.4% above its estimated fair value. The current Shares Outstanding (EOP) is 96.2 Mil. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current Shares Outstanding (EOP) is 96.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allied Biotech (ROCO:1780) Overvalued in 2026?

Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued. The current stock price of NT$22.30 is trading 7.4% above its estimated GF Value™ of NT$20.77. GuruFocus considers Allied Biotech to be Fairly Valued.

Key valuation signals for ROCO:1780:

  • Shares Outstanding (EOP): 96.2 Mil
  • GF Value™: NT$20.77 vs. price of NT$22.30 (7.4% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Allied Biotech Business Description

Address No. 76 Tun Hua S. Road, Sec. 2, 12th Floor, Taipei, TWN
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score

Get the complete analysis for ROCO:1780

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.30
Price
NT$20.77
GF Value